MALVERN, Pa., June 12 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL - News), a specialty pharmaceutical company, announced that new findings presented today at the American Diabetes Association’s 66th Annual Scientific Sessions suggest that abnormally low testosterone levels may be linked to progression of Type 2 diabetes. The data are obtained from patient screening for a prospective study and include 568 men with Type 2 diabetes. Researchers found a general increase in insulin resistance in patients with Type 2 diabetes who have low total testosterone levels, compared to Type 2 diabetes patients with normal total testosterone levels. Recent studies have highlighted the potential importance of androgen concentrations in relation to insulin sensitivity. This latest cohort analysis provides evidence of the need for additional investigation into the effects that testosterone replacement therapy has on insulin resistance, glucose regulation and progression of Type 2 diabetes. Data were presented today in a poster titled, “Comparison of Indices of Insulin Resistance and Insulin Secretion between Hypogonadal and Non-Hypogonadal Type II Diabetic Patients” (Abstract #606-P), at the American Diabetes Association’s 66th Annual Scientific Sessions in Washington, DC. The study was sponsored by Auxilium Pharmaceuticals, Inc.
